IDRA Baker Bros on board & Vincent Millano Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDRA Baker Bros on board & Vincent Millano

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: singhisking	11/23/2017 6:37:56 AM
	of 9

Idera Pharma initiated with a Buy at H.C. Wainwright; tgt $4 -- Targeting TLRs to modulate immune response (1.77) H.C. Wainwright initiates IDRA with a Buy and price target of $4. Idera Pharmaceuticals is a leader in developing therapies that target Tolllike receptors (TLRs) for oncologic and inflammatory indications. TLRs are expressed by immune cells to help them recognize pathogens and modulate the immune response. Idera's TLR agonist IMO-2125 is currently being tested in mid-stage clinical studies for its efficacy in oncologic indications. The company's TLR antagonist, IMO-8400, blocks TLRs to suppress over-activated immune response in pathologic inflammatory conditions. IMO-2125 and IMO-8400 both showed promising clinical activity and are currently in the Phase 2 studies for the treatment of PD-1 refractory melanoma and dermatomyositis, respectively. Idera's two lead products have significant potential in the fast growing immunotherapy market with projected risk-adjusted revenues in 2027 of $408M and $259M for IMO-2125 and IMO-8400, respectively. NOV 9, 2017

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next